Fibrinogen Concentrate Sales

Fibrinogen Concentrate Sales Market Outlook

The global fibrinogen concentrate market is projected to reach approximately USD 1.5 billion by 2035, expanding at a compound annual growth rate (CAGR) of about 8% during the forecast period from 2025 to 2035. Key drivers for this growth include the increasing prevalence of bleeding disorders and the rising number of surgical procedures that require fibrinogen supplementation. The growing awareness of the therapeutic benefits of fibrinogen concentrates, combined with advances in medical technologies making these products more accessible, are also significant contributors to market expansion. Additionally, the enhancement of healthcare infrastructure in emerging markets is expected to further bolster demand for fibrinogen concentrates. As innovative formulations and delivery technologies evolve, the market is positioned for robust growth in the coming decade.

Growth Factor of the Market

The growth of the fibrinogen concentrate market is significantly influenced by an increase in surgical procedures, which demand effective hemostatic agents to control bleeding. The rising incidence of congenital fibrinogen deficiency and trauma-related bleeding also drives demand for these products, as healthcare providers seek to mitigate complications associated with such conditions. Furthermore, ongoing research and development initiatives aimed at improving the efficacy of fibrinogen concentrates are likely to propel market growth. The increase in geriatric populations, who are more susceptible to bleeding due to various health conditions, further fuels the need for effective hemostatic solutions. Additionally, the adoption of advanced healthcare technologies and the shift towards more patient-centric care approaches are fostering a favorable environment for the market's expansion.

Key Highlights of the Market

• Projected to reach USD 1.5 billion by 2035 with a CAGR of 8%.
• Rising prevalence of congenital fibrinogen deficiency as a major growth factor.
• Increasing surgical procedures and trauma management applications driving demand.
• Advancements in healthcare infrastructure, especially in emerging markets.
• Growing focus on R&D for innovative fibrinogen formulations and delivery systems.

By Product Type

Human Fibrinogen Concentrate:

Human fibrinogen concentrate is derived from human plasma and is widely used in clinical settings due to its effectiveness in controlling bleeding. This type of concentrate is particularly beneficial in treating patients with congenital fibrinogen deficiency and is frequently utilized in surgical procedures where significant blood loss is expected. The high safety profile of human fibrinogen, owing to rigorous screening processes for disease transmission, further enhances its appeal in the healthcare sector. As surgical interventions continue to rise globally, the demand for human fibrinogen concentrate is anticipated to grow correspondingly, supported by positive clinical outcomes and a strong emphasis on patient safety.

Bovine Fibrinogen Concentrate:

Bovine fibrinogen concentrate is sourced from cattle and serves as an alternative to human-derived products, particularly in regions where human fibrinogen is scarce or more expensive. This concentrate is prominent in veterinary medicine as well, where it is used to treat bleeding disorders in animals. Although the application in human medicine is less common due to concerns about zoonotic transmission, bovine fibrinogen still plays a role in specific healthcare niches. The lower production costs associated with bovine fibrinogen could provide a competitive edge, especially in developing markets where affordability is a key issue.

Synthetic Fibrinogen Concentrate:

Synthetic fibrinogen concentrates are gaining traction due to their ability to provide a controlled and consistent product free from biological risks associated with human or animal sources. These concentrates are developed through advanced biotechnology and offer specific advantages such as enhanced safety profiles and targeted efficacy. As the demand for synthetic alternatives increases, especially among patients with high sensitivities to blood products, the synthetic fibrinogen segment is expected to witness substantial growth. Moreover, the innovation in synthetic product formulations is likely to lead to broader applications in various surgical and trauma management scenarios.

Porcine Fibrinogen Concentrate:

Porcine fibrinogen concentrate is derived from pigs and is utilized primarily in surgical applications and veterinary medicine. This type of concentrate can be favorable in certain scenarios due to its biochemical properties, which may mirror human fibrinogen closely. However, its adoption in human medicine is limited, mainly due to regulatory hurdles and ethical considerations regarding animal-derived products. Despite these challenges, porcine fibrinogen has a niche market, particularly in regions where alternatives are limited. The segment is anticipated to grow as more healthcare providers explore diverse fibrinogen sources in response to varying patient needs.

Others:

The 'Others' category encompasses various fibrinogen products that do not fall into the primary classifications mentioned above. This segment may include combination products or specialized fibrinogen formulations tailored for specific medical applications. The growth of this segment may be driven by ongoing innovations in the field of hemostatic agents, as well as increasing customization in patient care that allows for targeted therapies. As healthcare providers continue to seek effective and versatile solutions for managing bleeding, the 'Others' category is likely to see a gradual increase in market share.

By Application

Congenital Fibrinogen Deficiency:

Congenital fibrinogen deficiency is a rare but serious bleeding disorder that results from genetic mutations affecting fibrinogen production. The rising awareness of this condition and its implications for patient health have led to an increased focus on effective treatments, such as fibrinogen concentrates. Patients suffering from this deficiency often require ongoing management and supplementation, thus driving the demand for fibrinogen concentrates in this segment. As healthcare providers become more adept at diagnosing and managing congenital fibrinogen deficiency, a subsequent rise in treatment demand is anticipated, contributing to market growth.

Surgical Procedures:

The application of fibrinogen concentrates in surgical procedures is a significant driver of market growth. Surgeons rely on these products to minimize bleeding during complex operations, including orthopedic, cardiac, and neurosurgical interventions. The increasing number of elective and emergency surgeries globally necessitates the use of hemostatic agents like fibrinogen concentrates to ensure optimal patient outcomes. Additionally, the focus on reducing transfusion-related complications in surgical settings has heightened the importance of fibrinogen concentrates, reinforcing their role as essential components of modern surgical care.

Trauma & Bleeding Management:

Fibrinogen concentrates are vital in managing trauma and severe bleeding, particularly in emergency medicine settings where rapid intervention is critical. The increasing incidence of traumatic injuries, whether from accidents or conflict, underscores the need for effective hemostatic solutions to stabilize patients promptly. Healthcare facilities are increasingly incorporating fibrinogen concentrates into their protocols for trauma care, which is expected to bolster market growth significantly. The ongoing advancements in trauma care practices and the emphasis on rapid response mechanisms are likely to further enhance the utilization of fibrinogen concentrates in this application.

Cardiovascular Surgery:

In cardiovascular surgeries, managing blood loss is a primary concern, and fibrinogen concentrates are increasingly becoming a key component of surgical protocols. These concentrates help in achieving hemostatic control during procedures such as coronary artery bypass grafting or valve replacements. Given the escalating rates of cardiovascular diseases and the subsequent rise in surgical interventions, the demand for fibrinogen concentrates in this field is anticipated to grow. The positive outcomes associated with fibrinogen supplementation in maintaining adequate hemostasis during these surgeries will likely drive further adoption in the cardiovascular surgery application segment.

Others:

The 'Others' category in the application segment includes a variety of uses for fibrinogen concentrates that do not fall neatly into the primary classifications. This may encompass applications in wound care, dental surgeries, or even cosmetic procedures where hemostasis is crucial. As healthcare providers become more innovative in their approaches to patient care, alternative applications for fibrinogen concentrates are likely to emerge, providing additional avenues for market expansion. The exploration of new uses for fibrinogen products will enhance the segment's growth potential and contribute to the overall dynamics of the market.

By Distribution Channel

Hospitals:

Hospitals remain the primary distribution channel for fibrinogen concentrates due to their critical role in acute care settings, particularly in surgeries and trauma management. Hospitals typically maintain a stock of various hemostatic agents, including fibrinogen concentrates, to address the immediate needs of patients requiring surgical or emergency interventions. The ongoing expansion of hospital facilities and the increasing number of surgical operations performed annually significantly enhance the demand for fibrinogen concentrates within this channel. Furthermore, the integration of advanced inventory management systems in hospitals is expected to streamline the procurement process, ensuring a constant supply of these essential products.

Specialty Clinics:

Specialty clinics, particularly those focusing on hematology, wound care, or surgical specialties, are increasingly becoming important distribution channels for fibrinogen concentrates. These clinics cater to specific patient populations that may require tailored treatment approaches, including those with bleeding disorders or those undergoing certain types of surgeries. As the awareness of fibrinogen concentrates and their applications grows among healthcare providers and patients, specialty clinics are likely to witness a rising demand for these products. The focused nature of specialty clinics allows for personalized care, which can lead to improved patient outcomes and increased utilization of fibrinogen concentrates.

Retail Pharmacies:

Retail pharmacies are also exploring the distribution of fibrinogen concentrates, although this segment is still relatively nascent compared to hospitals and specialty clinics. As more patients become aware of their treatment options and seek out hemostatic agents for at-home use, retail pharmacies have the potential to expand their offerings. Collaboration with healthcare providers to ensure proper patient education and guidance is essential for the successful integration of fibrinogen concentrates into retail pharmacy settings. The convenience of access provided by retail pharmacies may drive a gradual increase in consumer demand for these products.

Online Pharmacies:

Online pharmacies represent a growing distribution channel for fibrinogen concentrates, leveraging the increasing trend towards e-commerce in healthcare. The convenience of purchasing medical products online, combined with the anonymity it provides to patients, could encourage more individuals to seek fibrinogen concentrates for their treatment needs. Nonetheless, the online distribution of such products requires stringent regulatory compliance and assurance of product quality to maintain patient safety. As telehealth services expand and more patients turn to online platforms for their healthcare needs, the online pharmacies segment is expected to witness notable growth in the coming years.

Others:

The 'Others' category in the distribution channel segment encompasses various unconventional methods of fibrinogen concentrate distribution, including direct sales to clinics or home care services. As healthcare delivery models evolve, innovative distribution strategies are likely to emerge, providing added flexibility for accessing these products. This segment may also include distribution through blood banks and medical supply companies that cater to niche markets. The diversification of distribution channels reflects the growing recognition of the importance of fibrinogen concentrates in various healthcare scenarios, and this trend is anticipated to continue as demand for such products rises.

By Ingredient Type

Plasma-derived Fibrinogen:

Plasma-derived fibrinogen is one of the most commonly used forms of fibrinogen concentrate, extracted from human blood plasma. This ingredient is preferred for its natural compatibility with the human body and its proven efficacy in clinical applications, particularly in managing bleeding disorders. The safety and effectiveness of plasma-derived products are bolstered by strict regulatory frameworks governing blood donation and processing. As more patients are diagnosed with conditions requiring fibrinogen supplementation, the demand for plasma-derived fibrinogen is expected to grow significantly over the next decade, making it a leading ingredient type in the market.

Recombinant Fibrinogen:

Recombinant fibrinogen is produced through genetic engineering techniques, allowing for the creation of a synthetic version of this crucial protein. The use of recombinant fibrinogen offers a significant advantage over plasma-derived options by eliminating the risks of disease transmission and immunologic reactions. As healthcare providers increasingly prioritize patient safety and product consistency, recombinant fibrinogen is anticipated to gain market share. The ongoing advancements in biotechnology are likely to yield more refined recombinant products, further enhancing their appeal in the healthcare setting, particularly in surgical and trauma applications.

Lyophilized Fibrinogen:

Lyophilized fibrinogen is a form of fibrinogen concentrate that has undergone freeze-drying, resulting in a stable powder that can be reconstituted for use. This form is advantageous for storage and transport, particularly in settings where refrigeration is not feasible. The lyophilization process preserves the functional properties of fibrinogen, making it suitable for various applications, including surgical interventions and emergency care. As the need for flexible and stable fibrinogen products grows, the lyophilized fibrinogen segment is expected to expand, providing healthcare professionals with a versatile option for managing bleeding effectively.

Others:

The 'Others' category in the ingredient type segment comprises novel fibrinogen formulations that may not fall under traditional classifications. This could include combination products or formulations that integrate fibrinogen with other agents to enhance efficacy. The development of these innovative products reflects the ongoing research in the field to create tailored solutions for specific medical conditions or patient needs. As the healthcare landscape evolves, the emergence of new ingredient types is likely to contribute to the overall growth of the fibrinogen concentrate market.

By Region

The North American fibrinogen concentrate market is poised for robust growth, driven by the increasing incidence of bleeding disorders and the rising number of surgical procedures. The market is projected to account for nearly 40% of the global fibrinogen concentrate revenue by 2035. The region benefits from advanced healthcare infrastructure, well-established distribution channels, and significant investments in research and development. Additionally, with a growing emphasis on patient safety and effective bleeding management, North America is likely to maintain its dominance in the fibrinogen concentrate landscape, supported by a CAGR of around 8.5% during the forecast period.

In Europe, the fibrinogen concentrate market is also expected to witness substantial growth, supported by an aging population and increasing post-operative care needs. The European market is projected to capture approximately 30% of global market share by 2035. Countries like Germany, France, and the UK are anticipated to lead the growth, driven by advancements in medical technologies and a strong focus on improving surgical outcomes. With a growing emphasis on patient-centered care, healthcare systems in Europe are increasingly adopting fibrinogen concentrates as essential components of treatment protocols, thereby enhancing the overall market landscape.

Opportunities

The fibrinogen concentrate market presents numerous opportunities driven by the ongoing advancements in medical technologies and the increasing prevalence of bleeding disorders. One significant opportunity lies in expanding the applications of fibrinogen concentrates beyond traditional uses, such as in wound care and rehabilitation settings. As healthcare providers explore innovative ways to manage various conditions, the versatility of fibrinogen products may lead to their adoption in a broader range of therapeutic areas. Moreover, the rise of telemedicine and home care solutions presents additional avenues for fibrinogen concentrates, as patients increasingly seek treatment options that can be integrated into their home healthcare regimens.

Additionally, the growing focus on global health initiatives aimed at improving access to healthcare in developing regions presents a strategic opportunity for companies operating in the fibrinogen concentrate market. As healthcare infrastructure continues to develop in emerging markets, the demand for effective and affordable hemostatic agents is expected to rise. Companies that can adapt their product offerings to meet the specific needs of these markets while ensuring compliance with local regulations stand to gain significant market share. Furthermore, partnerships with local healthcare providers and organizations can facilitate market entry and foster trust within these communities, translating to increased uptake of fibrinogen concentrates.

Threats

Despite the promising outlook for the fibrinogen concentrate market, several threats could impede growth. One major concern is the increasing competition from alternative hemostatic agents, such as tranexamic acid and other coagulation factors, which may offer similar benefits at a lower cost. As healthcare providers seek cost-effective solutions for bleeding management, the market share of fibrinogen concentrates could be adversely affected. Additionally, the emergence of novel technologies and treatment modalities in the field of hemostasis may shift preferences away from traditional fibrinogen products, leading to potential market disruption.

Another significant threat is the regulatory landscape surrounding blood-derived products, which can vary significantly between regions. Stricter regulations and lengthy approval processes may pose challenges for new entrants looking to introduce innovative fibrinogen formulations. Furthermore, concerns regarding bioethics and disease transmission associated with plasma-derived products could deter some healthcare providers from using fibrinogen concentrates derived from human or animal sources. Addressing these challenges will be crucial for sustaining market momentum in the face of evolving healthcare demands and regulatory scrutiny.

Competitor Outlook

• CSL Behring
• Octapharma AG
• Grifols S.A.
• Baxter International Inc.
• HemaCare Corporation
• Pfizer Inc.
• Roche Diagnostics
• Kedrion S.p.A.
• Biocryst Pharmaceuticals
• Shire (now part of Takeda Pharmaceutical Company)
• AccuBlood LLC
• Hoffmann-La Roche AG
• Prothena Corporation plc
• Hematogenix
• Serumwerk Bernburg AG

The competitive landscape of the fibrinogen concentrate market is characterized by the presence of several key players, each vying for market share through product innovation and strategic partnerships. Major companies such as CSL Behring and Octapharma AG are leading the market with well-established fibrinogen concentrate products that have garnered widespread acceptance among healthcare professionals. These companies have invested significantly in research and development to enhance the efficacy and safety profiles of their products, which has resulted in a strong foothold in various global markets. The competition is intensified by the ongoing trends toward patient-specific treatments, compelling companies to innovate continually and maintain compliance with stringent regulatory requirements.

Moreover, companies like Grifols S.A. and Baxter International Inc. are also prominent players in the fibrinogen concentrate market, benefiting from their extensive distribution networks and established relationships with healthcare institutions. These firms have adopted aggressive marketing strategies to promote their products and forge partnerships with hospitals and specialty clinics to ensure accessibility. Additionally, their focus on customer education and training for healthcare providers has helped to enhance the understanding and usage of fibrinogen concentrates in clinical settings. As the market becomes increasingly competitive, the ability to provide comprehensive support and innovative solutions is expected to separate leading companies from their competitors.

Furthermore, emerging companies and startups are entering the fibrinogen concentrate market, introducing novel formulations and delivery mechanisms that could disrupt the status quo. For example, companies such as Biocryst Pharmaceuticals and Prothena Corporation are exploring innovative technologies and alternative ingredient sources to enhance the therapeutic potential of fibrinogen concentrates. These new entrants are poised to challenge established players by offering differentiated products that cater to unmet medical needs. The influx of innovation in the market could lead to differentiated product offerings and heightened competition, ultimately benefiting patients through improved treatment options.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 CSL Behring
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hematogenix
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Grifols S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AccuBlood LLC
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Octapharma AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Kedrion S.p.A.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Diagnostics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 HemaCare Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hoffmann-La Roche AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Serumwerk Bernburg AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Biocryst Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Prothena Corporation plc
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Baxter International Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Shire (now part of Takeda Pharmaceutical Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Fibrinogen Concentrate Sales Market, By Application
    • 6.1.1 Congenital Fibrinogen Deficiency
    • 6.1.2 Surgical Procedures
    • 6.1.3 Trauma & Bleeding Management
    • 6.1.4 Cardiovascular Surgery
    • 6.1.5 Others
  • 6.2 Fibrinogen Concentrate Sales Market, By Product Type
    • 6.2.1 Human Fibrinogen Concentrate
    • 6.2.2 Bovine Fibrinogen Concentrate
    • 6.2.3 Synthetic Fibrinogen Concentrate
    • 6.2.4 Porcine Fibrinogen Concentrate
    • 6.2.5 Others
  • 6.3 Fibrinogen Concentrate Sales Market, By Ingredient Type
    • 6.3.1 Plasma-derived Fibrinogen
    • 6.3.2 Recombinant Fibrinogen
    • 6.3.3 Lyophilized Fibrinogen
    • 6.3.4 Others
  • 6.4 Fibrinogen Concentrate Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Fibrinogen Concentrate Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Fibrinogen Concentrate Sales market is categorized based on

By Product Type

• Human Fibrinogen Concentrate
• Bovine Fibrinogen Concentrate
• Synthetic Fibrinogen Concentrate
• Porcine Fibrinogen Concentrate
• Others

By Application

• Congenital Fibrinogen Deficiency
• Surgical Procedures
• Trauma & Bleeding Management
• Cardiovascular Surgery
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Plasma-derived Fibrinogen
• Recombinant Fibrinogen
• Lyophilized Fibrinogen
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• CSL Behring
• Octapharma AG
• Grifols S.A.
• Baxter International Inc.
• HemaCare Corporation
• Pfizer Inc.
• Roche Diagnostics
• Kedrion S.p.A.
• Biocryst Pharmaceuticals
• Shire (now part of Takeda Pharmaceutical Company)
• AccuBlood LLC
• Hoffmann-La Roche AG
• Prothena Corporation plc
• Hematogenix
• Serumwerk Bernburg AG